Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.53 |
| ▸ | CTSS | P25774 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | PRKX | P51817 | 1/20 | 0.47 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4353938 | 1.00 | CTSK (0.53) | CTSKCTSSMAPTATMPRKACA | |
| SCHEMBL56698 | 1.00 | CTSK (0.53) | CTSKCTSSMAPTATMPRKACA | |
| SCHEMBL21714668 | 0.92 | CTSK (0.51) | CTSKCTSSMAPTATMRIPK1 | |
| SCHEMBL4714695 | 0.92 | CTSK (0.51) | CTSKCTSSMAPTATMRIPK1 | |
| SCHEMBL14168716 | 0.89 | CTSK (0.51) | CTSKCTSSMAPTATMRIPK1 | |
| SCHEMBL4583120 | 0.88 | CTSK (0.53) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL4961187 | 0.88 | CTSK (0.56) | CTSKCTSSMAPTATMRIPK1 | |
| SCHEMBL28464584 | 0.88 | CTSK (0.53) | CTSKCTSSMAPTATMCTSL | |
| SCHEMBL127326 | 0.88 | RIPK1 (0.60) | CTSKCTSSMAPTATMRIPK1 | |
| SCHEMBL2481921 | 0.88 | RIPK1 (0.60) | CTSKCTSSMAPTATMRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230115837-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute | 2023-04-13 | — | — | US | disclosed |
| EP-4058454-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-09-21 | — | — | EP | disclosed |
| US-20210300935-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Nerviano Medical Sciences, S.R.L. (IT) | 2021-09-30 | — | — | US | disclosed |
| WO-2020236688-A1 | NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES | MERCK SHARP & DOHME CORP. (US) | 2020-11-26 | — | — | WO | disclosed |
| US-8394858-B2 | Cyclohexane derivatives and uses thereof | NOVARTIS AG (CH) | 2013-03-12 | — | — | US | disclosed |
| US-8394858-B2 | Cyclohexane derivatives and uses thereof | NOVARTIS AG (CH) | 2013-03-12 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20110136735-A1 | CYCLOHEXANE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | US | disclosed |
| US-20110136735-A1 | CYCLOHEXANE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| EP-1968940-A1 | 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300935-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | CTSK 965/4885CTSS 2805/4885MAPT 2476/4885 |
| US-20230115837-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | API5, XIAP, BIRC5 | CTSK 1675/4885CTSS 1471/4885MAPT 1661/4885 |
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | CTSK 863/4885CTSS 301/4885MAPT 1089/4885 |
| US-20110136735-A1 | CYCLOHEXANE DERIVATIVES AND USES THEREOF | CYP3A5, CYP11B2, CNR2 | CTSK 839/4885CTSS 587/4885MAPT 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.